E.U. Recommends Novartis' CV Combo Rasilamlo
This article was originally published in The Pink Sheet Daily
Executive Summary
European regulators recommend approval of yet another combination antihypertensive from Novartis as the Swiss company attempts to soften the loss of patent protection on its blockbuster Diovan.
You may also be interested in...
Efficacy Supplement Numbers On The Rise As Industry Braces For Patent Cliff
Drug makers are squeezing more new and expanded indications out of approved drugs to compensate for patent expiries and the lagging pace of new drug approvals, according to an analysis from the Tufts Center for the Study of Drug Development.
Efficacy Supplement Numbers On The Rise As Industry Braces For Patent Cliff
Drug makers are squeezing more new and expanded indications out of approved drugs to compensate for patent expiries and the lagging pace of new drug approvals, according to an analysis from the Tufts Center for the Study of Drug Development.
Novartis Sales Grow at Double Digits, Helped by Generics, Vaccines
A diversified business allows the Swiss group to report a 14% sales rise for 2010, although pharma sales growth was just half that